论文部分内容阅读
由于卫生行政部门的努力以及化学疗法的进步,肺结核的患病率、死亡率已有明显下降。但是患者中高龄者增加,常出现群体发病以致患病率下降不明显,成为耐药而长期排菌者等。因而期待着比目前各种抗结核药的副作用少而安全,没有交叉耐药性的强有力的药物问世。近年开发的OFLX(羟酸吡啶酮类合成抗菌剂)是对革兰氏阳性菌以及包括绿脓杆菌在内的革兰氏阴性菌都有效的强力广谱抗生素,对试管内部分抗酸杆菌有明显的抗菌作用,作者作了OFLX治疗肺结核的基础和临床研究,确有实效。从住院肺结核患者痰中分离到的109株菌株中,有108株在OFLX1.25μg/ml时显示敏感。还观察到5株堪萨斯菌全部在1.25μg/ml生长受到抑制。作者将可作为评价的18例患者作了分析。18例平
Due to the efforts of the health administrative departments and the advancement of chemotherapy, the prevalence and mortality rate of tuberculosis have dropped significantly. However, the elderly patients increased, often occur in groups so that the prevalence rate was not significantly reduced, become resistant to long-term bacteria and so on. It is therefore expected that more powerful and less drug-resistant drugs will be available than the current few side-effects of anti-TB drugs. OFLX (hydroxy pyridine pyridone synthetic antibacterial agent) developed in recent years is a powerful broad-spectrum antibiotic that is effective against both Gram-positive bacteria and gram-negative bacteria including Pseudomonas aeruginosa. Some of the acid-fast bacilli Obvious antibacterial effect, the author made OFLX treatment of tuberculosis based and clinical studies, indeed effective. Of 109 strains isolated from sputum of hospitalized patients with tuberculosis, 108 showed sensitivity at 1.25 μg / ml OFLX. It was also observed that all 5 Kansas bacteria were inhibited at 1.25 μg / ml growth. The authors analyzed 18 eligible patients for evaluation. 18 cases of flat